Tigatuzumab Biosimilar – Anti-TNFRSF10B, CD262 mAb – Research Grade

Description of Tigatuzumab Biosimilar - Anti-TNFRSF10B, CD262 mAb - Research Grade

Introduction

Tigatuzumab Biosimilar is a monoclonal antibody (mAb) that targets the tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), also known as CD262. This biosimilar is a research grade version of the original Tigatuzumab, which has been developed as a potential therapeutic for various types of cancer.

Structure of Tigatuzumab Biosimilar

Tigatuzumab Biosimilar is a humanized IgG1 monoclonal antibody, which means that it is composed of human and mouse components. The antibody is made up of two heavy chains and two light chains, which are connected by disulfide bonds. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of one constant domain (CL) and one variable domain (VL).

The variable domains of the antibody are responsible for binding to the target protein, TNFRSF10B. The constant domains are important for the effector functions of the antibody, such as binding to immune cells and activating the immune response.

Activity of Tigatuzumab Biosimilar

Tigatuzumab Biosimilar specifically targets TNFRSF10B, which is a cell surface receptor that plays a role in regulating cell death and survival. This receptor is overexpressed in many types of cancer, making it an attractive therapeutic target.

Once bound to TNFRSF10B, Tigatuzumab Biosimilar can induce cell death through various mechanisms, such as apoptosis, necroptosis, and autophagy. This makes it a potential treatment for cancers that are resistant to traditional therapies.

In addition, Tigatuzumab Biosimilar has been shown to have anti-angiogenic effects, meaning that it can inhibit the formation of new blood vessels that supply nutrients to tumors. This further contributes to its anti-tumor activity.

Application of Tigatuzumab Biosimilar

Tigatuzumab Biosimilar is currently being studied as a potential therapeutic for various types of cancer, including breast, lung, colon, and ovarian cancers. It has shown promising results in preclinical studies, and is now in clinical trials to evaluate its safety and efficacy in humans.

In addition to its potential as a standalone treatment, Tigatuzumab Biosimilar is also being investigated in combination with other cancer therapies, such as chemotherapy and radiation. This is because it has been shown to sensitize cancer cells to these treatments, making them more effective.

Conclusion

Tigatuzumab Biosimilar is a monoclonal antibody that targets TNFRSF10B, a cell surface receptor that is overexpressed in many types of cancer. It has shown promising results in preclinical studies and is now being evaluated in clinical trials as a potential treatment for various cancers. Its ability to induce cell death and inhibit angiogenesis make it a promising therapeutic option for cancer patients. Further research is needed to fully understand its potential and to determine the optimal dosing and treatment regimens for different types of cancer.